Compare ORMP & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORMP | ADAG |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.3M | 254.4M |
| IPO Year | 2010 | 2020 |
| Metric | ORMP | ADAG |
|---|---|---|
| Price | $4.28 | $3.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | ★ 175.5K | 130.9K |
| Earning Date | 05-14-2026 | 04-01-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ 412.50 | N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.87 | ★ N/A |
| Revenue Growth | ★ 49.25 | N/A |
| 52 Week Low | $1.98 | $1.44 |
| 52 Week High | $5.01 | $4.75 |
| Indicator | ORMP | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 56.62 | 40.20 |
| Support Level | $3.21 | $3.35 |
| Resistance Level | $5.01 | $3.53 |
| Average True Range (ATR) | 0.24 | 0.29 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 39.83 | 29.85 |
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.